Clinical trial
A Phase 2b, Double-Blind, Randomized, Placebo-Controlled, Dose-Finding Study, to Compare the Efficacy and Safety/Tolerability of CS1 Versus Placebo When Added to Standard of Care for the Treatment of Pulmonary Arterial Hypertension (PAH)
NCT07761572 is registered in ClinicalTrials.gov with Cereno Scientific AB as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2b, Double-Blind, Randomized, Placebo-Controlled, Dose-Finding Study, to Compare the Efficacy and Safety/Tolerability of CS1 Versus Placebo When Added to Standard of Care for the Treatment of Pulmonary Arterial Hypertension (PAH)
- Lead sponsor
- Cereno Scientific AB
- Phase
- Phase 2
- Overall status
- Not yet recruiting
- Start date
- September 15, 2026
- Completion date
- April 30, 2029
- Enrollment
- 126 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.